Drugs / ALT001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07476352 | May 2026 → Oct 2027 expected | multiple system atrophy | yilong Wang | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07514923 | Apr 2026 → Jan 2027 expected | multiple system atrophy, cerebellar type | yilong Wang | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07404891 | Mar → Jul 2026 overdue | osteoarthritis | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALT001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07476352 ↗ |
| Modality | Protein / enzyme biologic | “"ALT001" is a nerve repair protein developed by Darwin Start (Hubei) Biopharmaceutical Co., Ltd.” NCT07476352 ↗ |
| Route | Intrathecal | “According to the groups, patients would be treated with ALT001 via intrathecal injection or intravenous injection.” NCT07476352 ↗ |
| Route | Intravenous | “According to the groups, patients would be treated with ALT001 via intrathecal injection or intravenous injection.” NCT07476352 ↗ |